Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
An Open Label, Expanded Access Protocol Intended to Provide Treatment With MP-104 (Deflazacort) to U.S. Children, Adolescents, and/or Adults With Duchenne Muscular Dystrophy
Sponsor: Dohmen Life Science Services
Listed as NCT02592941, this observational or N/A phase trial focuses on Duchenne Muscular Dystrophy and remains ongoing. Sponsored by Dohmen Life Science Services, it has been updated 10 times since 2026, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Approved For Marketing
-
Sep 2024 — Sep 2025 [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jul 2024 [monthly]
Approved For Marketing
-
Jun 2018 — Jan 2021 [monthly]
Approved For Marketing
▶ Show 5 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Approved For Marketing
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Approved For Marketing NA
Status: Available → Approved For Marketing
-
Sep 2017 — Mar 2018 [monthly]
Available NA
-
Feb 2017 — Sep 2017 [monthly]
Available NA
-
Jan 2017 — Feb 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dohmen Life Science Services
- PTC Therapeutics
- Parexel
For direct contact, visit the study record on ClinicalTrials.gov .